MiMedx Group Inc (MDXG)

7.96
NASDAQ : Health Care
Prev Close 7.95
Day Low/High 7.83 / 8.06
52 Wk Low/High 6.64 / 10.02
Avg Volume 689.10K
Exchange NASDAQ
Shares Outstanding 109.51M
Market Cap 870.64M
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

MiMedx Group (MDXG) Shares Cross Above 200 DMA

MiMedx Group (MDXG) Shares Cross Above 200 DMA

In trading on Friday, shares of MiMedx Group Inc crossed above their 200 day moving average of $8.20, changing hands as high as $8.26 per share. MiMedx Group Inc shares are currently trading up about 0.9% on the day.

Benefits Of MiMedx DHACM Allograft Chronicled In Multiple Articles In February 2017 Supplement Edition Of Annals Of Plastic Surgery

Benefits Of MiMedx DHACM Allograft Chronicled In Multiple Articles In February 2017 Supplement Edition Of Annals Of Plastic Surgery

ARTICLES BY RENOWNED PHYSICIANS DEMONSTRATE THE CLINICAL BENEFITS OF dHACM ALLOGRAFTS IN BURN MANAGEMENT AND THE TREATMENT OF DIFFICULT TO HEAL WOUNDS

Scientific Study Confirms MiMedx DHACM Allograft Promotes Cardiac Repair Following Myocardial Infarction

Scientific Study Confirms MiMedx DHACM Allograft Promotes Cardiac Repair Following Myocardial Infarction

STUDY DEMONSTRATES THAT dHACM TREATMENT EFFECTS IMPROVED CELL SURVIVAL, ENHANCED VASCULARIZATION, AND RECRUITMENT OF AUTOLOGOUS STEM CELLS WITHIN INFARCTED CARDIAC TISSUE

First Week of September 15th Options Trading For MiMedx Group (MDXG)

First Week of September 15th Options Trading For MiMedx Group (MDXG)

Investors in MiMedx Group Inc saw new options become available this week, for the September 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

MDXG Crosses Below Key Moving Average Level

MDXG Crosses Below Key Moving Average Level

In trading on Wednesday, shares of MiMedx Group Inc crossed below their 200 day moving average of $8.25, changing hands as low as $8.03 per share. MiMedx Group Inc shares are currently trading off about 2.5% on the day.

MiMedx Fourth Quarter 2016 Revenue In Upper Range Of Guidance

MiMedx Fourth Quarter 2016 Revenue In Upper Range Of Guidance

$246.8 Million Full Year 2016 Revenue is a 32% Increase Over 2015 and $71.6 Million Q4 2016 Revenue is a 38% Increase Over Q4 2015

Interesting MDXG Put And Call Options For February 2017

Interesting MDXG Put And Call Options For February 2017

Investors in MiMedx Group Inc saw new options begin trading this week, for the February 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MDXG options chain for the new February 2017 contracts and identified one put and one call contract of particular interest.

MiMedx Comments On Meritless Lawsuit

MiMedx Comments On Meritless Lawsuit

MiMedx Applauds Passage Of 21st Century Cures Act

MiMedx Applauds Passage Of 21st Century Cures Act

Congress puts patients first in passing this groundbreaking legislation

MiMedx Announces USP-NF Monograph For DHACM Allografts Has Published

MiMedx Announces USP-NF Monograph For DHACM Allografts Has Published

MIMEDX'S PURION PROCESSED dHACM ALLOGRAFTS REPRESENT YEARS OF SCIENTIFIC RIGOR THAT CONFORM TO THE NEW USP-NF MONOGRAPH

Notable Two Hundred Day Moving Average Cross - MDXG

Notable Two Hundred Day Moving Average Cross - MDXG

In trading on Thursday, shares of MiMedx Group Inc crossed below their 200 day moving average of $8.03, changing hands as low as $7.87 per share. MiMedx Group Inc shares are currently trading down about 5.9% on the day.

MiMedx Is Grand Sponsor Of Desert Foot 2016

MiMedx Is Grand Sponsor Of Desert Foot 2016

MiMedx EpiFix®, AmnioFix®, AmnioFill™ and EpiCord™ Showcased for Wound Healing and Surgical Procedures

MiMedx Third Quarter 2016 Revenue Exceeds Upper End Of Guidance

MiMedx Third Quarter 2016 Revenue Exceeds Upper End Of Guidance

$64.4 Million Q3 2016 Revenue is 31% Increase Over Q3 2015

Advances In Regenerative Medicine With MiMedx EpiFix® And AmnioFix® To Be Presented At SAWC Fall Meeting

Advances In Regenerative Medicine With MiMedx EpiFix® And AmnioFix® To Be Presented At SAWC Fall Meeting

Presentation of Application Techniques and Therapeutic Approaches Using MiMedx EpiFix and AmnioFix for Wound Healing and Surgical Procedures

MiMedx Urges FDA To Reconsider Draft Guidances During Hearing

MiMedx Urges FDA To Reconsider Draft Guidances During Hearing

PRESENTERS OVERWHELMINGLY ASK FDA TO WITHDRAW OR SIGNIFICANTLY MODIFY DRAFT GUIDANCE